Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00568867 · ClinicalTrials.gov registry record
Evaluation of Preexisting Immunity Markers in Human Tumor Tissue Sample
A clinical trial of Cancer, sponsored by Stanford University.
- Completed
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT00568867: Completed study of Cancer, sponsored by Stanford University.
NCT00568867 is a study of Cancer that has completed, run by Stanford University. The registered enrollment target is 300 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00568867, a study of Cancer, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate markers of immune response in human tumor samples.
Conditions Studied
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00568867
The ClinicalTrials.gov registry entry for NCT00568867 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT00568867 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00568867 about?
NCT00568867 is a clinical study titled "Evaluation of Preexisting Immunity Markers in Human Tumor Tissue Sample". The purpose of this study is to evaluate markers of immune response in human tumor samples.
What is the current status of trial NCT00568867?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2006-09. Estimated completion is 2008-12.
What conditions does trial NCT00568867 study?
This clinical trial studies the following conditions: Cancer.
Who is sponsoring clinical trial NCT00568867?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00568867 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.